glp-1/fgf21 agonist boehringer Frontiers Glucagon-like peptide 1 (GLP-1) -

Description

The global market for GLP-1 weight-loss medications alone was valued at around $13.84 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 18.54%, reaching nearly $48.84 billion by 2030

Cardiovascular benefits

EMSs R$ 60 million Hortolndia plant opened in August 2024, and its tech-transfer pact with Fiocruz aims to supply 2 million biosimilar pens per year by 2028

2025 Exhibit 153: Provider-Administered Oncology Drugs, Prices of Biosimilars vs

This combination of enhanced focus, improved mood, and increased energy levels creates a positive feedback loop, with one user summarizing, "It boosted my energy and social interactions, making me more proactive and positive." Most participants dislike the current snack options in supermarkets Overall satisfaction with current snack options Most users don't like the snacks they can buy now